Core Insights - The company, Sihuan Pharmaceutical (02096), announced that its drug Enze Shu (injectable Suweisit monoclonal antibody) has been officially included in the National Medical Insurance Catalog for 2025, effective from January 1, 2026 [1] - Additionally, the drug Endu® (recombinant human vascular endothelial inhibitor injection) has successfully completed the renewal process for the National Medical Insurance Drug List (NRDL) [1] Drug Approvals and Indications - Enze Shu is a next-generation recombinant humanized anti-VEGF monoclonal antibody, approved for market in China on June 30, 2025 [1] - It is indicated for the treatment of adult patients with recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have received no more than one prior systemic therapy and are platinum-resistant, in combination with paclitaxel, liposomal doxorubicin, or topotecan [1] Market Position and Historical Context - Endu is recognized as China's first anti-angiogenesis targeted drug and the only endothelial inhibitor approved for sale globally [1] - Since its inclusion in the NRDL in 2017, Endu has become a cornerstone treatment for advanced non-small cell lung cancer [1]

Core Viewpoint - The announcement by the company indicates that its drug, Enze Shu (Suvorexant injection), has been officially included in the National Medical Insurance Catalog for 2025, effective from January 1, 2026, which is a significant milestone for the company and its product offerings [1] Group 1: Drug Approvals and Listings - Enze Shu has been approved for the treatment of adult patients with recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have received no more than one prior systemic therapy [1] - The drug was granted market approval in China on June 30, 2025, marking its entry into the market [1] - The company’s other drug, Endu (recombinant human vascular endothelial growth factor inhibitor injection), has successfully completed the renewal process for inclusion in the National Reimbursement Drug List (NRDL) [1] Group 2: Market Position and Significance - Enze Shu is a next-generation recombinant humanized monoclonal antibody targeting VEGF, which positions it as a novel treatment option in the oncology space [1] - Endu is recognized as China's first anti-angiogenesis targeted drug and the only endothelial inhibitor approved for sale globally, establishing it as a cornerstone treatment for advanced non-small cell lung cancer since its inclusion in the NRDL in 2017 [1]